Circ J. 2026 Jul 11. doi: 10.1253/circj.CJ-26-0460. Online ahead of print.
ABSTRACT
BACKGROUND: The clinical consequences of discontinuing proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have not been elucidated.
METHODS AND RESULTS: We analyzed 208 patients with coronary artery disease treated with PCSK9 inhibitors. During a median follow-up of 1,096 days, 94 patients discontinued treatment and they had a higher incidence of major adverse cardiovascular events (MACE) than those who continued. Event curves diverged approximately 3 years after discontinuation. Multivariable Cox analysis showed that discontinuation was associated with a higher incidence of MACE.
CONCLUSIONS: Discontinuation of PCSK9 inhibitors was associated with worse cardiovascular outcomes.
PMID:42438016 | DOI:10.1253/circj.CJ-26-0460